TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
RNA came to prominence during COVID-19 with mRNA vaccines saving millions of lives worldwide. Since then, the technology has evolved with some developers now focusing on personalized mRNA therapeutics ...
Upstream process intensification using perfusion cell culture has become a necessity for meeting today’s demand in monoclonal antibodies (mAbs) bioprocessing. By sustaining higher viable cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results